Payment overview · 2025
General Payments
$6,856.25
2 reported records · 1 companies
Healthcare provider profile · identity verified
Gary S Kabinoff, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · STUART, FL · NPI 1679540488
Verified facts
What the public records show
CMS Open Payments records show Gary S Kabinoff, M.D. received $6,856.25 in general payments during 2025 across 2 reported records.
Eli Lilly and Company accounted for 100.0% of that reported general-payment amount.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 15 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $6,856.25 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $6,856.25 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 11 recipient NPIs · example record 1186556234 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 536 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 497 | 150 |
| Atorvastatin Calcium | Atorvastatin Calcium | 315 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 81 |
| Losartan Potassium | Losartan Potassium | 240 | 81 |
| Citalopram Hbr | Citalopram Hydrobromide | 225 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 75 |
| Omeprazole | Omeprazole | 221 | 75 |
| Lisinopril | Lisinopril | 211 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 186 | 62 |
| Metformin Hcl | Metformin Hcl | 156 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 46 |
| Clonazepam | Clonazepam | 136 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 30 |
| Bupropion Xl | Bupropion Hcl | 124 | 38 |
| Simvastatin | Simvastatin | 122 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 120 | 35 |
| Prednisone | Prednisone | 115 | 83 |
| Allopurinol | Allopurinol | 114 | 33 |
| Alprazolam | Alprazolam | 113 | 31 |
| Gabapentin | Gabapentin | 103 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 33 |
| Potassium Chloride | Potassium Chloride | 89 | 26 |
| Synthroid | Levothyroxine Sodium | 88 | 27 |
| Ozempic | Semaglutide | 86 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 82 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 22 |
| Montelukast Sodium | Montelukast Sodium | 75 | 28 |
| Jardiance | Empagliflozin | 74 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 22 |
| Cephalexin | Cephalexin | 65 | 58 |
| Diazepam | Diazepam | 64 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 19 |
| Furosemide | Furosemide | 59 | 24 |
| Eliquis | Apixaban | 58 | 22 |
| Atenolol | Atenolol | 57 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 49 |
| Lorazepam | Lorazepam | 57 | 13 |
| Trazodone Hcl | Trazodone Hcl | 55 | 14 |
| Temazepam | Temazepam | 54 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 24 |
| Ezetimibe | Ezetimibe | 45 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 17 |
| Sertraline Hcl | Sertraline Hcl | 43 | 13 |
| Valsartan | Valsartan | 43 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 17 |
| Valacyclovir | Valacyclovir Hcl | 39 | 16 |
| Olanzapine | Olanzapine | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 31 |
| Celecoxib | Celecoxib | 34 | 12 |
| Memantine Hcl | Memantine Hcl | 34 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 24 |
| Azithromycin | Azithromycin | 32 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 27 |
| Donepezil Hcl | Donepezil Hcl | 31 | 12 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Carvedilol | Carvedilol | 29 | 12 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Meloxicam | Meloxicam | 29 | 18 |
| Xarelto | Rivaroxaban | 29 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | 11 |
| Ramipril | Ramipril | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 12 |
| Glimepiride | Glimepiride | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,856.25 · 2 records | Eli Lilly and Company | — | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Eli Lilly and Company?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error